Beta Bionics, Inc. (BBNX) stock
BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/301% above fair value
$14.72−0.49 (-3.22%)
Close on Nov 17, 2026Market cap $800.28MP/E –Yield –
Beta Bionics r&d expenses
Research and development expenses are spending on new products and technology.
Beta Bionics's R&D Expenses for the twelve months ending Sep 30, 2026 was $42.70M, up 26.1% year over year. For fiscal 2025 it was $34.79M, up 32.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.79M | +32.9% |
| FY2024 | Dec 31, 2024 | $26.18M | +45.9% |
| FY2023 | Dec 31, 2023 | $17.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $11.98M | +46.1% |
| Q2 FY2026 | Jun 30, 2026 | $10.24M | +15.4% |
| Q1 FY2026 | Mar 31, 2026 | $10.36M | +36.4% |
| Q4 FY2025 | Dec 31, 2025 | $10.13M | +10.0% |
| Q3 FY2025 | Sep 30, 2025 | $8.20M | +59.4% |
| Q2 FY2025 | Jun 30, 2025 | $8.87M | +39.7% |
| Q1 FY2025 | Mar 31, 2025 | $7.59M | +38.5% |
| Q4 FY2024 | Dec 31, 2024 | $9.21M | – |
| Q3 FY2024 | Sep 30, 2024 | $5.14M | – |
| Q2 FY2024 | Jun 30, 2024 | $6.35M | – |
| Q1 FY2024 | Mar 31, 2024 | $5.48M | – |
See a number that looks wrong?